A Multi-center, Randomized, Double-blind, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients With Dyslipidemia and Hypertension
Latest Information Update: 19 Mar 2024
At a glance
- Drugs JW 0101+C 2101 (Primary) ; Pitavastatin/valsartan
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Sponsors JW Pharmaceutical
Most Recent Events
- 14 Mar 2024 Status changed from recruiting to completed.
- 19 Apr 2022 New trial record